Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: Evaluation of cardiovascular events in a randomized trial-Reference-Cited by-同舟云学术

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: Evaluation of cardiovascular events in a randomized trial

Published:2011-05-31 Issue:5 Volume:45 Page:346-353
ISSN:0036-5599
Container-title:Scandinavian Journal of Urology and Nephrology
language:en
Short-container-title:Scandinavian Journal of Urology and Nephrology

Author:

Hedlund Per Olov¹,Johansson Robert²,Damber Jan Erik³,Hagerman Inger⁴,Henriksson Peter⁵,Iversen Peter⁶,Klarskov Peter⁷,Mogensen Peter⁸,Rasmussen Finn⁷,Varenhorst Eberhard⁹

Affiliation:

1. Department of Urology, Karolinska University Hospital Solna, Sweden

2. Oncologic Center, University Hospital, Umeå, Sweden

3. Department of Urology, Sahlgrens University Hospital, Gothenburg, Sweden

4. Department of Cardiology, Karolinska University Hospital Huddinge, Sweden

5. Department of Internal Medicine, Danderyd University Hospital, Sweden

6. Department of Urology, Rigshospitalet, Copenhagen, Denmark

7. Department of Urology, Herlev University Hospital, Denmark

8. Department of Urology, Frederiksberg Hospital, Copenhagen, Denmark

9. Department of Urology, Linköping University Hospital, Sweden

Publisher

Informa UK Limited